Based on these results, the ongoing Phase 3 GLORIOSA clinical trial (NCT05445778) is comparing MIRV/bevacizumab to bevacizumab alone as maintenance therapy in patients with high FRα expression, platinum-sensitive ovarian cancer.108 The combination of STRO-002 and bevacizumab is also under investigation in a Phase 1, open-label clinical trial in ovarian cancer (NCT05200364). Here, FOLR1 is linked to ovarian cancer.